| P50 | author | Massimo Libra | Q37842996 |
| | James A. McCubrey | Q42317570 |
| | Alberto M Martelli | Q56922777 |
| | Richard A. Franklin | Q68547480 |
| | Ferdinando Nicoletti | Q84521195 |
| | Linda S Steelman | Q114723345 |
| | Franca Stivala | Q114723350 |
| | Lyudmyla Drobot | Q115726591 |
| | Melissa Sokolosky | Q115726633 |
| | Kristin Stadelman | Q115726637 |
| | Stephen L Abrams | Q123366731 |
| | William H Chappell | Q123366743 |
| P2860 | cites work | Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation | Q24322925 |
| | Potential use of rapamycin in HIV infection | Q24606795 |
| | PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. | Q27824819 |
| | Multidrug resistance in cancer: role of ATP-dependent transporters | Q28208049 |
| | Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate | Q28301966 |
| | GSK3beta and aging liver | Q33588732 |
| | Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. | Q33716552 |
| | Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. | Q33823577 |
| | Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. | Q34017915 |
| | The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. | Q34024558 |
| | Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway | Q34173253 |
| | The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions | Q34285644 |
| | RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK. | Q34420665 |
| | Resveratrol: a multitargeted agent for age-associated chronic diseases. | Q34590533 |
| | Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo | Q34619763 |
| | Regulation of Akt signaling activation by ubiquitination | Q34799443 |
| | Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging | Q34966603 |
| | InAKTivation of insulin/IGF-1 signaling by dephosphorylation | Q35030359 |
| | EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). | Q35044994 |
| | Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells | Q35556981 |
| | Elevated PI3K signaling drives multiple breast cancer subtypes | Q35640263 |
| | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health | Q35679353 |
| | Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity | Q35679369 |
| | The complexity of PTEN: mutation, marker and potential target for therapeutic intervention | Q35976355 |
| | The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it? | Q36268324 |
| | Pharmacological breast cancer therapy (review). | Q36279863 |
| | Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer | Q36614997 |
| | PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects | Q37032524 |
| | PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches | Q37192606 |
| | Targeting the leukemic stem cell: the Holy Grail of leukemia therapy | Q37272565 |
| | Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. | Q37331720 |
| | mTORC1 signaling governs hematopoietic stem cell quiescence | Q37344758 |
| | Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists | Q37357692 |
| | Epithelial ovarian cancer: focus on genetics and animal models | Q37394549 |
| | The Akt kinases: isoform specificity in metabolism and cancer | Q37549798 |
| | Exploring Rak tyrosine kinase function in breast cancer. | Q37549835 |
| | The Par-4/PTEN connection in tumor suppression | Q37559086 |
| | Targeting mTOR globally in cancer: thinking beyond rapamycin | Q37630203 |
| | Targeting translation in acute myeloid leukemia: a new paradigm for therapy? | Q37637833 |
| | The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. | Q37732880 |
| | Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program | Q37781243 |
| | Non-genomic loss of PTEN function in cancer: not in my genes. | Q37828766 |
| | Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. | Q37837732 |
| | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. | Q37865381 |
| | Targeting the cancer initiating cell: The Achilles’ heel of cancer | Q39638171 |
| | AKT-ing via microRNA | Q39660049 |
| | Nutrient withdrawal rescues growth factor-deprived cells from mTOR-dependent damage | Q39663338 |
| | Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy | Q39739155 |
| | Cancer stem cells and escape from drug-induced premature senescence in human lung tumor cells: implications for drug resistance and in vitro drug screening models | Q39801897 |
| | Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence | Q39845659 |
| | Rapamycin decelerates cellular senescence | Q39846812 |
| | AKT1 mediates bypass of the G1/S checkpoint after genotoxic stress in normal human cells | Q39859253 |
| | Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro | Q39883174 |
| | The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells | Q39902046 |
| | The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia | Q39991646 |
| | ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells | Q40314359 |
| | Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. | Q40462527 |
| | Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. | Q40780780 |
| | mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging | Q41809553 |
| | The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway | Q41841005 |
| | The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer | Q42483340 |
| | Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. | Q43218096 |
| | Reduced expression of PTEN correlates with breast cancer progression | Q44017668 |
| | Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. | Q44246942 |
| | Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance | Q44358965 |
| | Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. | Q44419395 |
| | Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. | Q44545559 |
| | Both lipid- and protein-phosphatase activities of PTEN contribute to the p53-PTEN anti-invasion pathway | Q45908947 |
| | At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence. | Q45995695 |
| | Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration. | Q46008332 |
| | The role of the PI3K-PKB signaling module in regulation of hematopoiesis | Q46131483 |
| | High Affinity Binding of Inositol Phosphates and Phosphoinositides to the Pleckstrin Homology Domain of RAC/Protein Kinase B and Their Influence on Kinase Activity | Q57986498 |
| | Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus | Q74274255 |
| | Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast | Q80379623 |
| | Activation of PI3K/Akt signaling and hormone resistance in breast cancer | Q83930686 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 538-550 | |
| P577 | publication date | 2011-07-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy | |
| P478 | volume | 2 | |